Compaction of fibrin clots reveals the antifibrinolytic effect of factor XIII

Journal of Thrombosis and Haemostasis

Volumn 14, Issue 7, 2016, Pages 1453-1461

  Rijken, D C ^a   Abdul, S ^a   Malfliet, J J M C ^a   Leebeek, F W G ^a   Uitte de Willige, S ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

clot retraction; factor XIII; fibrinolysis; hemostasis; thrombosis

Indexed keywords

1,3 DIMETHYL 2 [(2 OXOPROPYL)THIO]IMIDAZOLIUM; ALPHA 2 ANTIPLASMIN; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 13A; BLOOD CLOTTING INHIBITOR; FIBRIN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ARTICLE; BLOOD CLOT LYSIS; BLOOD CLOT RETRACTION; CENTRIFUGATION; CONTROLLED STUDY; FIBRIN CLOT; FIBRINOLYSIS; HUMAN; PRIORITY JOURNAL; PROTEIN CROSS LINKING;

EID: 84990240254     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.13354     Document Type: Article

References (31)

1. Undas A, Ariens RA. Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases. Arterioscler Thromb Vasc Biol 2011; 31: e88–99.
2. Muszbek L, Bereczky Z, Bagoly Z, Komaromi I, Katona E. Factor XIII: a coagulation factor with multiple plasmatic and cellular functions. Physiol Rev 2011; 91: 931–72.
3. Lorand L. Fibrin clots. Nature 1950; 166: 694–5.
4. Shen LL, Hermans J, McDonagh J, McDonagh RP, Carr M. Effects of calcium ion and covalent crosslinking on formation and elasticity of fibrin cells. Thromb Res 1975; 6: 255–65.
5. Gladner JA, Nossal R. Effects of crosslinking on the rigidity and proteolytic susceptibility of human fibrin clots. Thromb Res 1983; 30: 273–88.
6. Ryan EA, Mockros LF, Weisel JW, Lorand L. Structural origins of fibrin clot rheology. Biophys J 1999; 77: 2813–26.
7. Kurniawan NA, Grimbergen J, Koopman J, Koenderink GH. Factor XIII stiffens fibrin clots by causing fiber compaction. J Thromb Haemost 2014; 12: 1687–96.
8. Hethershaw EL, Cilia La Corte AL, Duval C, Ali M, Grant PJ, Ariens RA, Philippou H. The effect of blood coagulation factor XIII on fibrin clot structure and fibrinolysis. J Thromb Haemost 2014; 12: 197–205.
9. Rijken DC, Lijnen HR. New insights into the molecular mechanisms of the fibrinolytic system. J Thromb Haemost 2009; 7: 4–13.
10. Haverkate F. Lysis of crosslinked and non-crosslinked purified fibrin. Thromb Diath Haemost 1975; 34: 584–5.
11. Francis CW, Marder VJ. Increased resistance to plasmic degradation of fibrin with highly crosslinked alpha-polymer chains formed at high factor XIII concentrations. Blood 1988; 71: 1361–5.
12. Siebenlist KR, Mosesson MW. Progressive cross-linking of fibrin gamma chains increases resistance to fibrinolysis. J Biol Chem 1994; 269: 28414–19.
13. Sakata Y, Aoki N. Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor. J Clin Invest 1980; 65: 290–7.
14. Sakata Y, Aoki N. Significance of cross-linking of alpha 2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis. J Clin Invest 1982; 69: 536–42.
15. Jansen JW, Haverkate F, Koopman J, Nieuwenhuis HK, Kluft C, Boschman TA. Influence of factor XIIIa activity on human whole blood clot lysis in vitro. Thromb Haemost 1987; 57: 171–5.
16. Fraser SR, Booth NA, Mutch NJ. The antifibrinolytic function of factor XIII is exclusively expressed through alpha(2)-antiplasmin cross-linking. Blood 2011; 117: 6371–4.
17. Reed GL, Houng AK. The contribution of activated factor XIII to fibrinolytic resistance in experimental pulmonary embolism. Circulation 1999; 99: 299–304.
18. Rampling MW, Flexman C. Factor XIII cross-linking and fibrinolytic rates. Thromb Res 1979; 16: 877–80.
19. Mutch NJ, Koikkalainen JS, Fraser SR, Duthie KM, Griffin M, Mitchell J, Watson HG, Booth NA. Model thrombi formed under flow reveal the role of factor XIII-mediated cross-linking in resistance to fibrinolysis. J Thromb Haemost 2010; 8: 2017–24.
20. Sakharov DV, Nagelkerke JF, Rijken DC. Rearrangements of the fibrin network and spatial distribution of fibrinolytic components during plasma clot lysis. Study with confocal microscopy. J Biol Chem 1996; 271: 2133–8.
21. Talens S, Malfliet JJ, Rudez G, Spronk HM, Janssen NA, Meijer P, Kluft C, de Maat MP, Rijken DC. Biological variation in tPA-induced plasma clot lysis time. Thromb Haemost 2012; 108: 640–6.
22. Lee KN, Jackson KW, Christiansen VJ, Chung KH, McKee PA. A novel plasma proteinase potentiates alpha2-antiplasmin inhibition of fibrin digestion. Blood 2004; 103: 3783–8.
23. Uitte de Willige S, Malfliet JJ, Deckers JW, Dippel DW, Leebeek FW, Rijken DC. Plasma levels of soluble fibroblast activation protein in arterial thrombosis: determinants and cleavage of its substrate alpha-2-antiplasmin. Int J Cardiol 2015; 178: 105–10.
24. Uitte de Willige S, Malfliet JJ, Janssen HL, Leebeek FW, Rijken DC. Increased N-terminal cleavage of alpha-2-antiplasmin in patients with liver cirrhosis. J Thromb Haemost 2013; 11: 2029–36.
25. Tsurupa G, Yakovlev S, McKee P, Medved L. Noncovalent interaction of alpha(2)-antiplasmin with fibrin(ogen): localization of alpha(2)-antiplasmin-binding sites. Biochemistry 2010; 49: 7643–51.
26. Gaffney PJ, Whitaker AN. Fibrin crosslinks and lysis rates. Thromb Res 1979; 14: 85–94.
27. Tamaki T, Aoki N. Cross-linking of alpha 2-plasmin inhibitor and fibronectin to fibrin by fibrin-stabilizing factor. Biochim Biophys Acta 1981; 661: 280–6.
28. Schroder V, Kohler HP. Effect of factor XIII Val34Leu on alpha2-antiplasmin incorporation into fibrin. Thromb Haemost 2000; 84: 1128–30.
29. Dunn EJ, Philippou H, Ariens RA, Grant PJ. Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus. Diabetologia 2006; 49: 1071–80.
30. Agren A, Jorneskog G, Elgue G, Henriksson P, Wallen H, Wiman B. Increased incorporation of antiplasmin into the fibrin network in patients with type 1 diabetes. Diabetes Care 2014; 37: 2007–14.
31. Rijken DC, Uitte de Willige S. Comment on Agren et al. Increased incorporation of antiplasmin into the fibrin network in patients with type 1 diabetes. Diabetes Care 2014;37:e243.2007–2014.